BioNTech SE22UA
▼ NegativeRegulationrelevance
Judge rejected BioNTech's bid to dismiss Monsanto's mRNA patent suit over its COVID-19 vaccine.
Impact on assets 5
Biotech & Genomic Medicine
BioNTech SE
Moderna IncMRNA
▼ NegativeRegulationrelevance
Judge rejected Moderna's bid to dismiss Monsanto's mRNA patent infringement suit over its COVID-19 vaccine.
Pfizer IncPFE
▼ NegativeRegulationrelevance
Judge rejected Pfizer's request to dismiss Monsanto's mRNA patent infringement lawsuit.
Johnson & JohnsonJNJ
Mentioned
Health Care
Bayer AG NABAYN
▲ PositiveRegulationrelevance
Bayer's Monsanto unit won the ruling allowing its mRNA patent infringement suits against Pfizer, BioNTech and Moderna to proceed.
Theme Impact 2
Off-coverage companies
Related news
United States▲2
Moderna Rejoins Nasdaq-100 as Juan Andres Returns as COO to Scale Cancer Vaccine
Moderna, Inc. was added back to the Nasdaq-100 index and announced that former manufacturing leader Juan Andres would return as Chief Operating Officer to oversee scaling for its personalized cancer vaccine candidate, intismeran autogene, following positive Phase 3 melanoma results. The COO appointment is the announcement most tied to Moderna's evolving story around intismeran autogene, with Andres's remit to oversee manufacturing and execution coming just as the cancer vaccine moves from promising Phase 3 data toward potential launch. Moderna's narrative projects $4.5 billion revenue and $780.4 million earnings by 2029, yielding a $122.67 fair value that implies a 45% downside to its current price. Some bullish analysts were already assuming revenue could reach about US$8.8 billion with positive earnings by 2029, far more optimistic than consensus. The combination of index inclusion and operational leadership focused on oncology suggests Moderna is entering a new phase of portfolio diversification beyond its initial COVID-19 vaccine focus, though the company remains unprofitable and core clinical and execution risks persist.
About megatrends
Biotech & Genomic Medicine › mRNA Platforms ▲Talent
Biotech & Genomic Medicine › RNA Therapeutics ▲Talent
Biotech & Genomic Medicine › Oncology Therapeutics ▲Talent
MRNA · Technology · Positive COO Juan Andres returns to oversee scaling of the personalized cancer vaccine intismeran autogene after positive Phase 3 melanoma results.
MRNA · Capital · Neutral Moderna rejoins the Nasdaq-100 index, a passive fund-flow event, while its projected $122.67 fair value implies 45% downside.
United StatesBecton Dickinson to Invest $3B in US Manufacturing as Viatris Buys Pacira for $1.65B
Becton Dickinson agreed to invest $3 billion to bring manufacturing of essential medical products to the United States, part of a broader plan to invest $19 billion in the country over several years across capital, operations and supply-chain initiatives, President Donald Trump said Monday in a post on Truth Social. More than $1 billion of that $3 billion will go to Nebraska to ramp up production of numerous products, including needles made with American steel, and BD expects to increase domestic production of essential medical consumables by about 5 billion units annually, raising the share of such products supplied from within the U.S. to roughly 80%. Separately, Viatris entered a definitive agreement to acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion, in a deal expected to close by the end of 2026 that adds the patent-protected pain therapies EXPAREL and ZILRETTA; Pacira generated approximately $746 million in total revenue and about $177 million in adjusted EBITDA in the twelve months ended June 30, 2026. CSL and Alentis Therapeutics entered an exclusive global partnership to co-develop and co-promote lixudebart for rare kidney, liver and other diseases, with CSL making an initial payment of $355 million and Alentis eligible for up to $1.2 billion in commercial milestone payments, and the companies sharing global profits 55% to CSL and 45% to Alentis once the drug is commercialized. Novavax and Moderna traded flat in the premarket on Tuesday after the WHO said Russian officials had traced all contacts of a plague research lab employee who died of pneumonia of an unknown cause, though Novavax closed 20% higher and Moderna added 7% on Monday after Russia's Rospotrebnadzor reported the death of the 28-year-old worker at the Irkutsk Research Anti-Plague Institute of Siberia.
About megatrends
Biotech & Genomic Medicine › Rare Disease ▲Supply
Biotech & Genomic Medicine › Vaccines (Recombinant & Traditional) Supply
Biotech & Genomic Medicine › mRNA Platforms Supply
BDX · Capital · Positive BD agreed to invest $3B in US manufacturing, part of a $19B multi-year US investment plan, boosting domestic production capacity.
PCRX · Capital · Positive Viatris agreed to acquire all Pacira shares for $36.50 per share in cash, a $1.65B equity deal.
VTRS · Capital · Positive Viatris entered a definitive agreement to acquire Pacira for $1.65B, adding EXPAREL and ZILRETTA pain therapies.
Alentis Therapeutics · Technology · Positive Alentis partnered with CSL to co-develop and co-promote lixudebart, receiving $355M upfront and up to $1.2B in milestones.
CSL Limited · Technology · Positive CSL entered an exclusive global partnership with Alentis to co-develop and co-promote lixudebart for rare diseases.
United States▲
Moderna Fair Value Estimate Rises to US$122.67 on Cancer Vaccine Analyst Revisions
Moderna's fair value estimate has been lifted from US$119.56 to US$122.67 per share, according to updated modelling tied to analyst revisions on its intismeran cancer vaccine program. The change follows Phase 3 INTerpath-001 melanoma data that prompted target lifts or upgrades from BofA, Goldman Sachs, UBS, Barclays, RBC Capital and Morgan Stanley, with BofA setting a US$200 target and a Neutral rating and calling the readout a watershed moment for Moderna. William Blair moved to Outperform and Wolfe Research called the melanoma result de-risking for the broader intismeran platform, while RBC Capital described the data as a massive scientific breakthrough. On the bearish side, Citi and Rothschild & Co Redburn moved to Sell even as they raised targets to US$80 and US$81 respectively, citing questions on oncology revenue expectations and limited disclosure around efficacy metrics such as hazard ratios. The updated model also shifted the revenue growth assumption from 26.74% to 26.75%, the net profit margin from 17.25% to 17.20%, the future P/E from 80.90x to 83.10x, and the discount rate from 7.50% to 7.46%.
About megatrends
Biotech & Genomic Medicine › Oncology Therapeutics ▲Technology
Biotech & Genomic Medicine › mRNA Platforms ▲Technology
Biotech & Genomic Medicine › RNA Therapeutics ▲Technology
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint Technology
MRNA · Capital · Positive Fair value estimate raised to US$122.67 and multiple analyst price-target increases/upgrades followed the data readout.
MRNA · Technology · Positive Phase 3 INTerpath-001 melanoma data for the intismeran cancer vaccine prompted analyst target lifts and upgrades, de-risking the platform.
United States▲2
Moderna shares surge on news of US-private partnership to develop cancer vaccines
Shares of Moderna and Novavax rose today after The New York Times reported that the US National Institutes of Health, or NIH, plans to launch a public-private partnership to accelerate the development of personalized cancer vaccines. The vaccine project is expected to begin in December, focusing on pancreatic cancer, liver cancer, and colorectal cancer, as well as certain tumors in children. Previous trials have used mRNA technology to train the body's immune system to recognize and attack proteins specific to cancer cells. The positive reaction to the news was most evident for Moderna, which is developing personalized mRNA cancer vaccines together with Merck. Moderna's share price has soared more than 600% since the start of this year, making it the best-performing stock among the companies used to calculate the S&P 500 index.
About megatrends
Biotech & Genomic Medicine › mRNA Platforms ▲Technology
Biotech & Genomic Medicine › RNA Therapeutics ▲Technology
Biotech & Genomic Medicine › Oncology Therapeutics ▲Technology
MRNA · Technology · Positive NIH public-private partnership to accelerate personalized mRNA cancer vaccines directly benefits Moderna's cancer vaccine program with Merck.
NVAX · Technology · Positive Novavax shares rose on the NIH cancer vaccine partnership news, though the article does not detail its specific role.
United States▲2
Moderna to Join Nasdaq-100, Replacing Warner Bros. Discovery
Moderna will join the Nasdaq-100 Index on Oct. 9, replacing Warner Bros. Discovery before the opening bell on Friday. The swap follows the completion of Paramount's acquisition of Warner Bros. Discovery, whose shares have ceased trading; the combined entity is now named Skydance and trades on the NYSE under the ticker SKYD. Nasdaq did not cite a specific reason for adding Moderna, but the inclusion follows a sharp rise in the company's market value and growing optimism around its prospects, supported by positive phase III results for its personalized cancer therapy developed with Merck, which met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in certain high-risk melanoma patients. The Nasdaq-100 is tracked by more than 200 investment products with over $800 billion in assets under management globally, so index funds adjusting their portfolios could create incremental institutional demand for Moderna shares. The inclusion does not change Moderna's underlying fundamentals, operations, cash flow or pipeline development, and the stock's longer-term performance will continue to depend on its business and pipeline. Moderna shares have skyrocketed 566% year-to-date, far outpacing the industry's 1% growth, and the stock trades at 30.84 times forward 12-month sales on a price-to-sales basis versus an industry average of 2.06 times.
About megatrends
Biotech & Genomic Medicine › mRNA Platforms ▲Capital
Biotech & Genomic Medicine › RNA Therapeutics ▲Capital
Biotech & Genomic Medicine › Oncology Therapeutics ▲Capital
MRNA · Capital · Positive Moderna will join the Nasdaq-100 on Oct. 9, and index funds tracking the index could create incremental institutional demand for its shares.
WBD · Capital · Neutral Warner Bros. Discovery is being removed from the Nasdaq-100 after Paramount completed its acquisition and its shares ceased trading.
United States▲
Tempus Expands Multi-Year Collaboration with Moderna and Merck for Intismeran Autogene
Tempus announced an expanded, multi-year collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene, also known as V940 or mRNA-4157, a potential first-in-class individualized neoantigen therapy being evaluated in combination with KEYTRUDA in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside the United States and Canada, and the new collaboration builds on joint efforts initiated last year. Under the agreement, Tempus will manage the timely collection and transfer of tumor tissue and blood samples required for next-generation sequencing, and, subject to applicable regulatory approvals, will also provide NGS services to support the intismeran autogene design and manufacturing process. Financial terms of the collaboration were not disclosed. Moderna Chief Business Officer Said Francis said the partnership lets the company leverage Tempus's commercial footprint and advanced sequencing capabilities, while Jannie Oosthuizen, President of Global Oncology and MSD International, said such collaborations are helping build the infrastructure needed to bring individualized neoantigen therapies to patients at scale.
About megatrends
Biotech & Genomic Medicine › mRNA Platforms ▲Supply
Biotech & Genomic Medicine › Oncology Therapeutics ▲Supply
Biotech & Genomic Medicine › RNA Therapeutics ▲Supply
Biotech & Genomic Medicine › Diagnostics & Precision Testing ▲Supply
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Supply
TEM · Demand · Positive Tempus wins an expanded multi-year collaboration to provide tissue/blood collection and NGS services for intismeran autogene.
MRK · Demand · Positive Expanded collaboration supports commercialization of intismeran autogene, which Merck co-develops with Moderna and evaluates with KEYTRUDA.
MRNA · Demand · Positive Moderna's jointly developed intismeran autogene gains Tempus support for sample collection, NGS design, and manufacturing toward commercialization.